FindDrugs.org

WellMedr Review

Brand-level review · Last reviewed Sep 21, 2026

5.76/10

Operator-trust score

The brand-level factors every category shares — legitimacy, clinical oversight, transparency, privacy, policy, support — not price or per-treatment value.

Cash-pay

Our verdict

WellMedr is one of the more forthcoming operators in compounded GLP-1 telehealth on the things that are hardest to find out — who prescribes, who fills the prescription, and exactly when money stops being refundable — and one of the least forthcoming on the thing that is easiest to publish, which is the price. A reader who wants to know what treatment costs before handing over a card cannot find out from this site.

WellMedr plans & reviews by category

Each category is scored separately. Read the full review where one exists — or check current pricing directly.

Weight Loss / GLP-1

5.17/10
Read the Weight Loss / GLP-1 reviewCheck price
  • Compounded GLP-1 (injectable semaglutide) · injectionnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Compounded GLP-1/GIP (injectable tirzepatide) · injectionnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Compounded Oral GLP-1 (oral semaglutide) · oralnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Compounded Oral GLP-1/GIP (oral tirzepatide) · oralnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Zepbound · injectionnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Ozempic · injectionnot published — every product variant on the storefront is priced at zero and no figure appears in the page copy; the price is reached only inside the intake and checkout
  • Energy & Focus+ (microdose tirzepatide with NAD+ and vitamin B12) · injection$199/mo
  • LipoForce+ (microdose tirzepatide with B12, methionine and inositol) · injection$199/mo

Prices as of Sep 21, 2026 — verify current on the brand's site.

Key takeaways

  • Names both its clinical network and its fulfilment pharmacy, which most of this category does not do
  • Publishes no price for any core GLP-1 treatment before checkout; two combination products show $199 a month
  • Takes payment before its own clinical review, then refunds it in full automatically if treatment is declined
  • The 21-day plan is not monthly and can bill up to eighteen times in a year, which the brand states plainly
  • Three pairs of live pages contradict each other, including on whether the medications are FDA approved

What is WellMedr?

WellMedr is a cash-pay telehealth service operated by Wellmedr LLC of St. Petersburg, Florida. It sells compounded semaglutide and compounded tirzepatide in both injection and oral tablet form, a line of low-dose "microdose" blends that combine those molecules with vitamins, and month-to-month plans for the branded medications Zepbound and Ozempic. Clinical care is delivered by OpenLoop Health, a licensed medical group and provider network, and prescriptions are filled by a named fulfilment pharmacy. Beyond weight management the same account also sells testosterone, sexual-health, hair-loss and peptide treatments.

Is WellMedr legit?

WellMedr is a real, identifiable business that discloses more of its supply chain than most of this category: it names its operating entity and street address, its clinical network and its fulfilment pharmacy, and it publishes the weight-loss disclosure Florida law requires. It carries no third-party accreditation, it publishes no price before checkout, and several of its own pages contradict one another.

  • Corporate identity: Wellmedr LLC is named as the operating entity at 7901 4th Street North, Suite 300, St. Petersburg, Florida, with a toll-free phone number and two support addresses.
  • Clinicians and pharmacy: OpenLoop Health is named as the medical group and provider network, with its three affiliated covered entities listed, and Mycelium Pharmacy is named as the fulfilment pharmacy. Neither the pharmacy’s regulatory category nor any individual clinician is identified.
  • Regulatory record: FindDrugs searched the FDA’s enforcement register for WellMedr and Wellmedr LLC on 21 September 2026 and found no entry. The same register returned eleven letters for a control search on semaglutide, so the absence is a measurement rather than a gap in our checking. We did not search the federal court docket this run.
  • Watch-outs: No third-party accreditation is claimed anywhere on the site and none was verified. The compounded products it sells are not FDA-approved — its own safety page and footer say so — yet its general FAQ tells readers the opposite.

Treatment options

What WellMedr actually treats. Pricing lives in the plans table above and in each category review.

  • Weight management

    compounded semaglutide and compounded tirzepatide, injection or oral tablet; branded Zepbound and Ozempic on month-to-month plans; low-dose microdose blends

  • Testosterone

    prescription testosterone therapy, not yet reviewed

  • Sexual health

    compounded ED treatments, not yet reviewed

  • Hair loss

    prescription hair-restoration treatment, not yet reviewed

Pros & cons

Pros

  • Names OpenLoop Health as its clinical network and Mycelium Pharmacy as its fulfilment pharmacy
  • Refund rules are specific and favourable where the clinician declines treatment
  • Publishes a detailed GLP-1 safety page with the boxed warning and the major contraindications
  • Discloses that compounded semaglutide and tirzepatide are not FDA-approved, in several places and in plain words
  • Offers a genuine low-dose entry point rather than only standard starting doses

Cons

  • No published price for the core GLP-1 treatments
  • Payment is taken before WellMedr’s own clinical review decides whether treatment is appropriate
  • Beyond an 18-or-over rule, no BMI or clinical eligibility criterion is published before paying
  • A tolerability claim for the microdose line sits on the same page as a statement that those formulations have not been studied
  • No individual clinician or medical director is named

The bottom line

WellMedr suits someone who has already decided on compounded GLP-1 treatment, wants to know who will prescribe it and who will fill it, and is willing to enter an intake before finding out what it costs. Anyone who wants a price before a card goes in, or a published eligibility threshold before paying, should look elsewhere in this category.

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 21, 2026Initial scoremethodology v65.76

    WellMedr's Operator Trust Score first recorded at 5.76 out of 10 — the earliest score in this log.

Review score changes

The timeline above is this brand's Operator Trust Score. Each review below is scored separately, and keeps its own history.

  • Weight Management / GLP-1 review— no recorded score change yet

Work at WellMedr?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Completeness was not recorded for this score · 15 sources cited

Brand site

Regulatory

What we couldn't verify

  • No price is published. Each of the four core GLP-1 products returns a single storefront variant priced at zero and the page copy carries no figure. The price appears only inside the intake and at checkout, and reaching it means driving the questionnaire in a rendered browser — which we do not do on a host whose terms refuse automated access. The two $199 figures we do cite are on combination microdose products, not the core treatments.
  • The minimum age is published (18 or over); the BMI threshold and the clinical criteria are not, on any page we read. They are applied inside the intake by the clinical network, and the same rendering restriction applies as for price.
  • The fulfilment pharmacy is named but its regulatory category is not stated anywhere on the site, and we did not attempt to verify the pharmacy’s licence.
  • The state corporate registry returned HTTP 403 to our retrieval. We hold no terms reading for that host, so under default-deny we did not render it. The registration is unverified — not absent.
  • The federal-docket check ran on 2026-09-21 against the CourtListener REST API v4 (the only sanctioned route — courtlistener.com is refused on terms), with the positive control "Mochi Health" returning 15 records, so a zero result from this run is a measurement and not a failed search. It found one entry naming WellMedr as a party: KOLMIND, LTD. v. WELLMEDR, LLC, District of New Jersey, removed to federal court on 2026-09-10 (Notice of Removal; subject of the underlying complaint not yet available). WHAT THIS DOES NOT ESTABLISH: the retrievable record carries the caption, the court and the filing date and nothing more — nature of suit and cause are both empty — so the subject of the case, its merits and whether it concerns patients, medicine or a commercial dispute are all unknown. No score reflects it, because scoring a filing whose subject we could not read would be inventing the part we could not read. Separately, WellMedr's clinician network OpenLoop Healthcare Partners PC is named as a party in 4 records, including Burley v. OpenLoop Healthcare Partners, PC (D. Nev., 2025-07-16); those concern the network, not WellMedr.
  • The review platform that carries the volume refuses automated access in its terms, and we do not render a host that refuses us. A figure surfaced by a search engine is not a reading of the page, so none is cited.
  • The fifty-state claim is the brand’s own and its FAQ states a narrower position. We did not verify it against state licence records.
  • Neither figure carries a source on the page. The brand states elsewhere that its published results reflect comparable telehealth brands rather than its own studies, and that the microdose formulations have not been studied for specific health outcomes. Recorded as unsourced brand claims; FindDrugs neither repeats them as fact nor disputes them.
Last reviewed Sep 21, 2026View the ledger